3 results
Approved WMOCompleted
To determine the pharmacokinetic properties of a new elacridar formulation
Approved WMOCompleted
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
Approved WMOCompleted
The primary objective of this proof of concept study is to test the feasibility of using the gamma-prototype of the lower limb exoskeleton XoSoft during locomotion-tasks related to daily life in stroke and iSCI patients in a controlled environment.…